| Asthma
Advair HFA vs Trelegy Ellipta
Side-by-side clinical, coverage, and cost comparison for asthma.Deep comparison between: Advair Hfa vs Trelegy Ellipta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTrelegy Ellipta has a higher rate of injection site reactions vs Advair Hfa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Trelegy Ellipta but not Advair Hfa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Advair Hfa
Trelegy Ellipta
At A Glance
Oral inhalation
Twice daily
ICS/LABA combination
Oral inhalation
Once daily
ICS/LAMA/LABA
Indications
- Asthma
- Chronic Obstructive Airway Disease
- Asthma
Dosing
Asthma 2 oral inhalations (45 mcg/21 mcg, 115 mcg/21 mcg, or 230 mcg/21 mcg) twice daily approximately 12 hours apart; starting strength based on asthma severity; maximum 2 inhalations of 230 mcg/21 mcg twice daily.
Chronic Obstructive Airway Disease 1 actuation of TRELEGY ELLIPTA 100/62.5/25 mcg once daily by oral inhalation; rinse mouth with water without swallowing after each dose.
Asthma 1 actuation of TRELEGY ELLIPTA 100/62.5/25 mcg or 200/62.5/25 mcg once daily by oral inhalation; rinse mouth with water without swallowing after each dose.
Contraindications
- Primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required
- Hypersensitivity to any ingredient of ADVAIR HFA
- Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required
- Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone furoate, umeclidinium, vilanterol, or any excipient
Adverse Reactions
Most common (>=3%) Upper respiratory tract infection, throat irritation, headache, nausea and vomiting, musculoskeletal pain, upper respiratory inflammation, viral respiratory infection, hoarseness/dysphonia, dizziness, viral gastrointestinal infection, gastrointestinal signs and symptoms, muscle pain
Serious Serious asthma-related events (hospitalizations, intubations, death), oropharyngeal candidiasis, pneumonia in COPD patients, immunosuppression and risk of infections, hypercorticism and adrenal suppression, cardiovascular and CNS effects, reduction in bone mineral density, growth effects, glaucoma and cataracts
Postmarketing Arrhythmias, hypertension, ventricular tachycardia, Cushing's syndrome, osteoporosis, cataracts, glaucoma, anaphylaxis, esophageal candidiasis, paradoxical bronchospasm, agitation, depression
Most common (>=1%) Headache, back pain, nasopharyngitis, upper respiratory tract infection, bronchitis, dysgeusia, cough, oropharyngeal pain, diarrhea, influenza, sinusitis, oral candidiasis, arthralgia, dysphonia, pneumonia, urinary tract infection, rhinitis, constipation, gastroenteritis
Serious Serious asthma-related events (hospitalizations, intubations, death), oropharyngeal candidiasis, pneumonia in COPD, immunosuppression and risk of infections, hypercorticism and adrenal suppression, paradoxical bronchospasm, cardiovascular effects, reduction in bone mineral density, worsening of narrow-angle glaucoma, worsening of urinary retention
Postmarketing Palpitations, blurred vision, eye pain, glaucoma, intraocular pressure increase, hypersensitivity reactions (anaphylaxis, angioedema, rash, urticaria), hyperglycemia, muscle spasms, tremor, anxiety, dysuria, urinary retention
Pharmacology
ADVAIR HFA combines fluticasone propionate, a synthetic trifluorinated corticosteroid with broad anti-inflammatory activity via glucocorticoid receptor binding, and salmeterol, a selective long-acting beta2-adrenoceptor agonist (LABA) that relaxes bronchial smooth muscle by stimulating adenyl cyclase to increase cyclic AMP levels.
TRELEGY ELLIPTA combines fluticasone furoate (ICS), umeclidinium (long-acting muscarinic antagonist), and vilanterol (LABA); fluticasone furoate reduces airway inflammation via glucocorticoid receptor activation, umeclidinium produces bronchodilation through M3 muscarinic receptor inhibition, and vilanterol relaxes bronchial smooth muscle through beta2-adrenergic receptor stimulation and increased cyclic AMP.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Advair Hfa
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (12/12)
Trelegy Ellipta
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Advair Hfa
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (5/8)
Trelegy Ellipta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Advair Hfa
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Trelegy Ellipta
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Advair Hfa.
No savings programs available for Trelegy Ellipta.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Advair HfaView full Advair Hfa profile
Trelegy ElliptaView full Trelegy Ellipta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.